MLM Biologics

MLM Biologics Inc. is a Delaware C-Corporation that develops and manufactures advanced wound care solutions based on proprietary collagen scaffold technology. The company's flagship product is bio-ConneKt® Wound Matrix, an FDA-cleared, sterile collagen-based wound closure device indicated for a broad range of acute, chronic, trauma, surgical, and burn wounds, including diabetic foot ulcers, venous ulcers, and pressure ulcers. bio-ConneKt® is manufactured in an ISO 13485-certified facility and holds reimbursement coding (HCPCS Level II Q-code) from the Centers for Medicare and Medicaid Services. The company employs a proprietary processing platform based on expertise in scaffold chemistry and biology to deliver cost-effective, clinically proven solutions for wound closure. Product features include user-friendly storage, extended shelf-life, point-of-use application, and compatibility with negative pressure wound therapy (NPWT). MLM Biologics also pursues complementary development in sports medicine, orthopedics, and general surgery. As of December 2023, BioWound Solutions acquired exclusive US sales and marketing rights to bio-ConneKt®. The company has received significant recognition, including nearly $1.5 million in funding from the U.S. Army Medical Research and Development Command (USAMRDC) for development of infection-prevention devices for battlefield wounds.